Avilamycin and Cross-Resistance to Everninomicin
Author Information
Author(s): Thomas R. Shryock
Primary Institution: Elanco Animal Health
Hypothesis
Does avilamycin confer cross-resistance to everninomicin?
Conclusion
Avilamycin shows incomplete cross-resistance to everninomicin, and its use in animals does not pose a significant threat to public health.
Supporting Evidence
- 100% of 4,208 enterococcal isolates from patients in Europe were susceptible to Ziracin.
- 99.5%-100% of 6,030 isolates from various bacteria were susceptible to Ziracin.
Takeaway
Avilamycin is an antibiotic used in animals, and while it can make some bacteria less sensitive to another antibiotic, it doesn't completely stop them from being treated with it.
Methodology
Surveys of enterococcal isolates and other bacteria were conducted to assess susceptibility to avilamycin and everninomicin.
Limitations
The conclusions are based on surveys and the early developmental status of Ziracin.
Participant Demographics
Isolates from patients in 27 European countries and 33 laboratories worldwide.
Want to read the original?
Access the complete publication on the publisher's website